- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Fullspan Health on Winning the AI Search Revolution | ||
| Mo | Why AI and Precision Matter in Pharma Commercialization | ||
| Mo | Beyond the Pharmacy Counter: Inmar's Data Advantage | ||
| Mo | Beyond Data: Understanding the "Why" Behind HCP Decisions | ||
| Mo | Why MRC Accreditation Is Just the First Step | ||
| Mo | Why Medical Affairs Is Becoming Biopharma's Third Pillar | ||
| Mo | From Data Rich to Decision Ready in Life Sciences | ||
| Fr | GSK commits $800M to R&D, manufacturing hub, as Pennsylvania bonds deepen | ||
| Fr | Quince Therapeutics relaunches as IRulya, going all in on lung disease after Hail Mary merger | ||
| Fr | FDA's Rasonque review documents pressure RevMed as investors jitter over KRAS subgroup data | ||
| Fr | Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives | ||
| Fr | Fierce Pharma Asia-Novartis' $7.8B mRNA deal; Shionogi's $2B buy; ArriVent's phase 3 flop | ||
| Fr | Pharma's free lunches for clinicians bloat prescription bills: Cochrane review | ||
| Do | BMS fills out Zenbexus picture with post-approval PFS victory in multiple myeloma | ||
| Do | Viatris to snap up Pacira's non-opioid pain pipeline for $1.65B | ||
| Do | Pfizer's Tukysa snags first-line approval in HER2+ breast cancer | ||
| Do | CSL Seqirus blasted for 'multiple and prolonged deficiencies' | ||
| Do | Argenx walks away from Vyvgart Sjögren's disease trial after futility flag | ||
| Do | Melissa explains it all in menopause team up with Bayer | ||
| Do | Theramex pays up to $250M for Asieris' novel cervical lesion treatment | ||
| Mi | Novartis' Rhapsido tackles 2 most common forms of chronic hives with swift FDA expansion | ||
| Mi | Sanofi drafts NY Knicks star Karl-Anthony Towns for COVID, Nuvaxovid awareness push | ||
| Mi | Halozyme stymies subcutaneous Keytruda launch in select European countries as Merck vows to fight patent claims | ||
| Mi | How drugmakers are tapping into the GLP-1 frenzy's unprecedented 'consumer overlay' | ||
| Mi | New API Innovation Center index spotlights supply chain stress points |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.